Lost in translation: Animal models and clinical trials in cancer treatment

American Journal of Translational Research

Volumn 6, Issue 2, 2014, Pages 114-118

  Mak, Isabella W Y ^a,b   Evaniew, Nathan ^a,b   Ghert, Michelle ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

Animal models; Cancer; Clinical trials; Review; Translational studies

Indexed keywords

ALLOVECTIN; ANTINEOPLASTIC AGENT; CANCER VACCINE; MAGE A3; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY CD28; SARIDEGIB; TECEMOTIDE; TELOVAC; UNCLASSIFIED DRUG;

ANIMAL MODEL; CANCER GROWTH; CANCER RESEARCH; CANCER THERAPY; CARCINOGENESIS; CLINICAL PRACTICE; DRUG SAFETY; HUMAN; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SURVIVAL RATE; TRANSLATIONAL RESEARCH;

EID: 84892960440     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Junod SW. FDA and Clinical Drug Trials: A Short History. In: U.S. Food and Drug Administration; 2013.
2. General Considerations for Clinical Trials ICH Topic E8. In: ICH Guidance For Industry: Health Canada; 1998.
3. Ledford H. Translational research: 4 ways to fix the clinical trial. Nature 2011; 477: 526-8.
4. Arrowsmith J. Trial watch: phase III and submission failures: 2007-2010. Nat Rev Drug Discov 2011; 10: 87.
5. Curt GA, Chabner BA. One in five cancer clinical trials is published: a terrible symptom--what's the diagnosis? Oncologist 2008; 13: 923-4.
6. Thomas D. Oncology Clinical Trials-Secrets of Success. In: BIOtechNOW: Biotechnology Industry Organization; 2012.
7. Matthews RA. Medical progress depends on animal models-doesn't it? J R Soc Med 2008; 101: 95-8.
8. Perel P, Roberts I, Sena E, Wheble P, Briscoe C, Sandercock P, Macleod M, Mignini LE, Jayaram P, Khan KS. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ 2007; 334: 197.
9. Sena ES, van der Worp HB, Bath PM, Howells DW, Macleod MR. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol 2010; 8: e1000344.
10. Hackam DG, Redelmeier DA. Translation of research evidence from animals to humans. JAMA 2006; 296: 1731-2.
11. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. In: Food and Drug Administration: U.S. Department of Health and Human Services; 2004.
12. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, Lopez CM, Honari S, Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB, Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein BH, Miller-Graziano C, Calvano SE, Mason PH, Cobb JP, Rahme LG, Lowry SF, Maier RV, Moldawer LL, Herndon DN, Davis RW, Xiao W, Tompkins RG; Inflammation and Host Response to Injury, Large Scale Collaborative Research Program Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 2013; 110: 3507-12.
13. Schuh JC. Trials, tribulations, and trends in tumor modeling in mice. Toxicol Pathol 2004; 32 Suppl 1: 53-66.
14. Gawrylewski A. The Trouble with Animal Models. The Scientist 2007.
15. Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des 2007; 13: 333-46.
16. Chesler EJ, Wilson SG, Lariviere WR, Rodriguez-Zas SL, Mogil JS. Identification and ranking of genetic and laboratory environment factors influencing a behavioral trait, thermal nociception, via computational analysis of a large data archive. Neurosci Biobehav Rev 2002; 26: 907-23.
17. Attarwala H. TGN1412: From Discovery to Disaster. J Young Pharm 2010; 2: 332-6.
18. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018-28.
19. Wagner AHP, Okuno S, Eriksson M, Shreyaskumar P, Ferrari S, Casali P, Chawla S, Woehr M, Ross R, O'Keeffe J, Hillock A, Demetri G, Reichardt P. Results from a phase 2 randomized, placebo-controlled, double blind study of the hedgehog (HH) pathway antagonist IPI-926 in patients (PTS) with advanced chondrosarcoma (CS). In: Connective Tissue Oncology Society 18th Annual Meeting. New York, NY; 2013.
20. Tarpey PS, Behjati S, Cooke SL, Van Loo P, Wedge DC, Pillay N, Marshall J, O'Meara S, Davies H, Nik-Zainal S, Beare D, Butler A, Gamble J, Hardy C, Hinton J, Jia MM, Jayakumar A, Jones D, Latimer C, Maddison M, Martin S, McLaren S, Menzies A, Mudie L, Raine K, Teague JW, Tubio JM, Halai D, Tirabosco R, Amary F, Campbell PJ, Stratton MR, Flanagan AM, Futreal PA. Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. Nat Genet 2013; 45: 923-6.
21. Lee MJ, Hatton BA, Villavicencio EH, Khanna PC, Friedman SD, Ditzler S, Pullar B, Robison K, White KF, Tunkey C, LeBlanc M, Randolph-Habecker J, Knoblaugh SE, Hansen S, Richards A, Wainwright BJ, McGovern K, Olson JM. Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model. Proc Natl Acad Sci U S A 2012; 109: 7859-64.
22. Overall CM, Kleifeld O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 2006; 94: 941-6.
23. Dorman G, Cseh S, Hajdu I, Barna L, Konya D, Kupai K, Kovacs L, Ferdinandy P. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs 2010; 70: 949-64.
24. Vonderheide RH, Nathanson KL. Immunotherapy at large: the road to personalized cancer vaccines. Nat Med 2013; 19: 1098-100.
25. Yaddanapudi K, Mitchell RA, Eaton JW. Cancer vaccines: Looking to the future. Oncoimmunology 2013; 2: e23403.
26. Cavallo F, Offringa R, van der Burg SH, Forni G, Melief CJ. Vaccination for treatment and prevention of cancer in animal models. Adv Immunol 2006; 90: 175-213.
27. Ogi C, Aruga A. Immunological monitoring of anticancer vaccines in clinical trials. Oncoimmunology 2013; 2: e26012.
28. Oncothyreon Announces that L-BLP25 (Stimuvax®) Did Not Meet Primary Endpoint of Improvement in Overall Survival in Pivotal Phase 3 Trial in Patients with Non-Small Cell Lung Cancer. In: Oncothyreon Inc.; 2012.
29. The investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoint in Phase III melanoma clinical trial. In: GlaxoSmithKline plc.; 2013.
30. Vical Phase 3 Trial of Allovectin® Fails to Meet Efficacy Endpoints. In: Vical Inc.; 2013.
31. Phase III Failure for TeloVac Pancreatic Cancer Vaccine. In: Genetic Engineering & Biotechnology News; 2013.
32. Cook N, Jodrell DI, Tuveson DA. Predictive in vivo animal models and translation to clinical trials. Drug Discov Today 2012; 17: 253-60.
33. Marchetti S, Schellens JH. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. Br J Cancer 2007; 97: 577-81.
34. Wood C. Is Animal Testing about to become Obsolete? In: Casey Research; 2011.
35. Orenstein D. 'Microfluidic' chips may accelerate biomedical research. In: Stanford Report: Stanford University; 2006.
36. Gorman J. U.S. Will Not Finance New Research on Chimps. In: The New York Times; 2011.
37. Toxicity Testing in the 21st Century: A Vision and a Strategy. In: National Academy of Sciences; 2007.